Similar articles

• Structure-function analysis of time-resolved immunological phases in metabolic dysfunction-associated fatty liver disease (MASH) comparing the NIF mouse model to human MASH.

  Schmidt-Christensen A, Eriksson G, Laprade WM, Pirzamanbein B, Hörnberg M, Linde K, Nilsson J, Skarsfeldt M, Leeming DJ, Mokso R, Verezhak M, Dahl A, Dahl V, Önnerhag K, Oghazi MR, Mayans S, Holmberg D. Schmidt-Christensen A, et al. Sci Rep. 2024 Oct 3;14(1):23014. doi: 10.1038/s41598-024-73150-z. Sci Rep. 2024. PMID: 39362932 Free PMC article.
• When the liver is in poor condition, so is the heart - cardiac remodelling in MASH mouse models.

  Bott S, Lallement J, Marino A, Daskalopoulos EP, Beauloye C, Esfahani H, Dessy C, Leclercq IA. Bott S, et al. Clin Sci (Lond). 2024 Sep 18;138(18):1151-1171. doi: 10.1042/CS20240833. Clin Sci (Lond). 2024. PMID: 39206703 Free PMC article.
• Hepatic-specific Pgc-1α ablation drives fibrosis in a MASH model.

  Arconzo M, Piccinin E, Pasculli E, Cariello M, Loiseau N, Bertrand-Michel J, Guillou H, Matrella ML, Villani G, Moschetta A. Arconzo M, et al. Liver Int. 2024 Oct;44(10):2738-2752. doi: 10.1111/liv.16052. Epub 2024 Jul 24. Liver Int. 2024. PMID: 39046166
• Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10.

  Yang Y, Lu J, Liu Y, Zhang N, Luo Y, Ma M, Dong Z, Zhang S, Zheng MH, Ruan CC, Wan X, Hu C, Lu Y, Ma X, Zhou B. Yang Y, et al. Mol Metab. 2024 Nov;89:102030. doi: 10.1016/j.molmet.2024.102030. Epub 2024 Sep 16. Mol Metab. 2024. PMID: 39293565 Free PMC article.
• Mixed active metabolites of the SNP-6 series of novel compounds mitigate metabolic dysfunction-associated steatohepatitis and fibrosis: promising results from pre-clinical and clinical trials.

  Ho HT, Shih YL, Huang TY, Fang WH, Liu CH, Lin JC, Hsiang CW, Chu KM, Hsiong CH, Chen GJ, Wu YE, Hao JY, Liang CW, Hu OY. Ho HT, et al. J Transl Med. 2024 Oct 14;22(1):936. doi: 10.1186/s12967-024-05686-7. J Transl Med. 2024. PMID: 39402603 Free PMC article. Clinical Trial.